Search Results for: cnsp

CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit”

CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications”

CNS Pharmaceuticals (NASDAQ: CNSP) a biopharmaceutical company targeting brain and CNS cancers, reported a full-year 2024 net loss of $14.9 million, down from $18.9 million in 2023, due to reduced R&D spending. Despite Berubicin missing its primary endpoint in a glioblastoma multiforme (GBM) trial, the drug demonstrated safety and comparable efficacy, guiding future analysis. The … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances TPI 287 for GBM, Ends 2024 with Strong Cash Position”

CNS Pharmaceuticals (NASDAQ: CNSP) announced that CEO John Climaco will present at the 18th Annual European Life Sciences CEO Forum in Zurich on Feb. 26, 2025, at 3:20 p.m. CET / 9:20 a.m. EST; management will also be available for one-on-one meetings with registered investors, and a video webcast of the presentation will be accessible … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at European Life Sciences CEO Forum”

CNS Pharmaceuticals (NASDAQ: CNSP) announced its participation in the Virtual Investor Top 5 for ‘25 On-Demand Conference, where CEO John Climaco outlined five key reasons for investors and industry peers to follow the company in 2025. The presentation focused on CNS Pharmaceuticals’ advancements in developing treatments for primary and metastatic brain and central nervous system … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights 2025 Outlook at Virtual Investor Conference”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company developing treatments for brain and central nervous system cancers, will host a Virtual Analyst & Investor Day on December 11 from 11:30 a.m. to 1 p.m. ET. The event will feature presentations by the company’s leadership team, including CEO John Climaco, Chief Medical Officer Dr. Sandra Silberman, and … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Host Virtual Analyst & Investor Day on December 11”

CNS Pharmaceuticals (NASDAQ: CNSP) reported Q3 2024 financial results and highlighted clinical advancements, including the ongoing potentially pivotal trial of Berubicin, a targeted chemotherapy for recurrent glioblastoma multiforme (“GBM”). Enrollment of 252 patients was completed, with primary analysis data expected in the first half of 2025. Berubicin, which crosses the blood-brain barrier, has received Fast … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advances Glioblastoma Treatment with Berubicin Amid Strong Financial Position”

CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the Nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). This extension allows CNS additional time to regain compliance and maintain its listing status. To view the full press release, visit … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension for Compliance”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be participating in the upcoming 2024 Healthcare Virtual Summit. The summit, which is presented by Maxim Group LLC, is scheduled for Oct. 16, 2024. According to the announcement, … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Fireside Chat at 2024 Healthcare Virtual Summit”

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST … Continue reading “QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum”